Table 5.
Osteoporosis drug administration before and after propensity score matching for each group.
| Administrated drug | RA | Non-RA | P-value |
|---|---|---|---|
| Before propensity score matching | |||
| Denosumab | 168 (60.2) | 227 (55.5) | 2.195 × 10−1 |
| Bisphosphonate | 7 (2.5) | 39 (9.5) | 2.912 × 10−2 |
| SERM | 6 (2.2) | 3 (0.7) | 1.082 × 10−1 |
| Daily teriparatide | 2 (0.7) | 5 (1.2) | 5.164 × 10−1 |
| Weekly teriparatide | 1 (0.4) | 5 (1.2) | 2.314 × 10−1 |
| Drug naïve | 88 (31.5) | 130 (31.8) | 9.462 × 10−1 |
| Total | 279 | 409 | |
| After propensity score matching | |||
| Denosumab | 66 (60.7) | 65 (50.0) | 7.186 × 10−2 |
| Bisphosphonate | 1 (0.9) | 2 (3.8) | 7.286 × 10−1 |
| SERM | 2 (1.9) | 0 (0) | N/A |
| Daily teriparatide | 0 (0) | 0 (0) | N/A |
| Weekly teriparatide | 0 (0) | 1 (1.9) | N/A |
| Drug naïve | 38 (35.5) | 40 (37.0) | 5.565 × 10−1 |
| Total | 107 | 108 | |
Values are presented as number (%).
RA, a patient group who was suffered from rheumatoid arthritis; non-RA, a patient group who was not suffered from rheumatoid arthritis; SERM, selective estrogen-receptor modulator; N/A, not applicated.
In statistical significance column, RA > non-RA demonstrates significantly greater in the RA group than in the non-RA group within 5%, and RA < non-RA demonstrates significantly greater in the non-RA group than in the RA group within 5%.